<DOC>
	<DOCNO>NCT00792740</DOCNO>
	<brief_summary>The study conduct accord randomize , double-blind placebo-controlled , parallel group design 25 clinical site Europe . Patients randomly assign two parallel treatment group ( 1:1 randomization ratio ) receive either ITF2357 , hard gelatine capsule oral administration , dose 50 mg b.i.d . ( total daily dose 100 mg ) , match placebo capsule , . Treatment administer outpatient basis 8 consecutive week , follow 4-week follow-up . During screen , 8-week treatment period 4-week follow-up period , patient attend schedule visit , physical laboratory assessment , order monitor disease evolution safety tolerability ITF2357 . The study conduct 80 patient gender , establish diagnosis CD , present ulceration great aphthous ulcer least one five bowel segment investigate endoscopically , ileum rectum , endoscopic clinical evidence moderate-to-severe active disease , control on-going treatment conventional therapy 5-aminosalycylates , steroid immunosuppressant .</brief_summary>
	<brief_title>Multicenter , Randomized , Double-blind , Placebo-controlled Study Evaluate Effect ITF2357 Mucosal Healing Patients With Moderate-to-severe Active Crohn 's Disease</brief_title>
	<detailed_description>ITF2357 orally active , synthetic inhibitor histone deacetylase ( HDAC ) enzyme , demonstrate selectively inhibit in-vitro production pro-inflammatory cytokine exhibit in-vivo anti-inflammatory effect , animal human . Crohn 's Disease ( CD ) chronic debilitate inflammatory disease gastrointestinal tract unknown aetiology . The disease , affect slightly females male peak incidence 30 year age , lead significant physical morbidity mark impairment quality life . Abdominal pain diarrhoea common symptom , although patient CD may also develop number clinical feature malnutrition , anemia , osteoporosis , disable perianal fistula , extra-intestinal symptom fatigue , low-grade fever , arthritis abnormality liver function . CD may affect part gastrointestinal tract characterise pattern relapse remission may require treatment , include surgical intervention . More 70 % subject require surgery course disease . The present study design order prove short-term ( 8 week ) treatment oral ITF2357 induce disease improvement substantial proportion patient . Its aim evaluate whether short term treatment ITF2357 8 week , select dose 50 mg b.i.d. , able induce heal mucosal lesion , evaluate endoscopically , patient endoscopic clinical evidence moderate-to-severe active Crohn 's disease , control ongoing treatment conventional therapy 5-aminosalycylates , steroid immunosuppressant .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Givinostat hydrochloride</mesh_term>
	<criteria>Age : &gt; 18 year Diagnosis CD , reestablish endoscopy and/or Xray and/or surgery last 36 month CD active phase since least 2 week screen CDAI 220 450 CDEIS &gt; 8 Ulcerations great aphthous ulcer least 1 bowel segment ileum rectum If ongoing treatment corticosteroid ( prednisone , prednisolone budesonide ) , must dose equivalent less 30 mg/day prednisone , 9 mg budesonide , use least one month stable dose least two week patient enrolment If ongoing treatment immunosuppressant ( azathioprine , 6mercaptopurine , methotrexate ) , must use least 3 month patient enrolment If ongoing treatment 5aminosalicilates , must place least 4 week patient enrolment , dose &gt; 2 g Females childbearing potential negative pregnancy test Treatment 2 month antiTNFalfa antibody previous 3 month cytokine inhibitor experimental drug Primary failure previous treatment antiTNFalfa antibody Current bowel obstruction condition may predispose development ( e.g . clinically significant unresolved intestinal stricture , adhesion condition would place patient risk develop overt bowel obstruction ) intestinal perforation significant GI hemorrhage Expected surgery duration study Any ostomy extensive bowel resection Positive serological antiHCV antiHIV test positive test active HBV replication , e.g . HBVDNA HBsAg HBeAg ( perform screening ) Other ongoing clinical relevant viral infection ( e.g . herpes zoster , EpsteinBarr , CMV ) , systemic fungal infection history recurrent serious bacterial infection Signs symptom severe , progressive uncontrolled renal , hepatic , haematologic , endocrine , pulmonary , cardiac , neurologic cerebral disease Any previous evidence , irrespective severity , coronary disease , cardiac rhythm abnormality congestive heart failure QTc interval &gt; 450 msec pretreatment evaluation Serum magnesium potassium LLN pretreatment evaluation Platelet count 200 x 10^9/L pretreatment evaluation Any previous evidence , irrespective severity , renal function impairment Unavoidable concomitant treatment drug know potential risk cause Torsades de Pointes Presence transplant organ History cancer le 5 year documentation diseasefree state History tuberculosis Severe lactose intolerance Pregnant nursing woman Female childbearing potential without use safe contraceptive measure Participation clinical trial within 30 day prior initiation study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>88 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>